Ocular Therapeutix(OCUL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OCUL Ocular Therapeutix

交易中 07-23 12:37:23 EDT

8.57

-0.01

-0.17%

最高8.64	最低8.32	成交量81.35万
今开8.50	昨收8.59	日振幅3.73%
总市值18.76亿	流通市值15.77亿	总股本2.19亿
成交额687.13万	换手率0.44%	流通股本1.84亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OCUL","market":"US","secType":"STK","nameCN":"Ocular Therapeutix","latestPrice":8.57,"timestamp":1784824637957,"preClose":8.585,"halted":0,"volume":813455,"delay":0,"changeRate":-0.0017472335468841662,"floatShares":184000000,"shares":218906099,"eps":-1.449114,"marketStatus":"交易中","change":-0.015,"latestTime":"07-23 12:37:23 EDT","open":8.5,"high":8.6399,"low":8.32,"amount":6871295.871205,"amplitude":0.037263,"askPrice":8.57,"askSize":325,"bidPrice":8.56,"bidSize":125,"shortable":3,"etf":0,"ttmEps":-1.449114,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1784836800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1406260800000,"exchange":"NASDAQ","adjPreClose":8.585,"preHourTrading":{"tag":"盘前","latestPrice":8.5,"preClose":8.585,"latestTime":"09:29 EDT","volume":1858,"amount":15974.021224000002,"timestamp":1784813399918,"change":-0.085,"changeRate":-0.009901,"amplitude":0.043098},"postHourTrading":{"tag":"盘后","latestPrice":8.6418,"preClose":8.585,"latestTime":"19:34 EDT","volume":27898,"amount":239635.5535,"timestamp":1784763250853,"change":0.0568,"changeRate":0.006616,"amplitude":0.006616},"volumeRatio":0.799952,"impliedVol":0.9986,"impliedVolPercentile":0.7331},"requestUrl":"/m/hq/s/OCUL","defaultTab":"news","newsList":[{"id":"1117854803","title":"Ocular Therapeutix计划通过505(B)(2)途径提交新药申请，有望加速审评流程长达60天","url":"https://stock-news.laohu8.com/highlight/detail?id=1117854803","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117854803?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:48","pubTimestamp":1781700512,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix公司宣布，计划依据505监管途径提交其新药申请。这一策略选择有望将审评时间线最多缩短60天，从而可能加快其候选产品进入市场的步伐。505途径允许申办方部分依赖美国食品药品监督管理局对已获批药品的安全性及有效性数据，同时提交自身的新临床数据。相较于传统的505新药申请，该路径通常能提供更高效、资源需求更少的审评流程。对于Ocular Therapeutix而言，采用此途径标志着其产品开发策略的关键一步，旨在优化监管时间表并提升效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157065067","title":"Ocular Therapeutix投资者日将重点展示与FDA就Axpaxli™新药申请达成一致，计划于2026年第四季度提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1157065067","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157065067?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:45","pubTimestamp":1781700330,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix宣布，即将举行的投资者日活动将重点展示其与**美国食品药品监督管理局**就**Axpaxli™**新药申请所达成的共识。公司计划于**2026年第四季度**正式提交该申请。这一进展标志着该候选药物在监管路径上迈出了关键一步，备受投资者关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111843183","title":"Ocular Therapeutix 2026年一季度末现金及等价物达6.667亿美元，资金预计可支撑至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1111843183","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111843183?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:07","pubTimestamp":1777979230,"startTime":"0","endTime":"0","summary":"生物制药公司Ocular Therapeutix宣布，截至2026年3月31日，公司持有的现金及现金等价物总额为6.667亿美元。基于目前的资金状况和运营计划，公司预计现有资金足以支持其运营活动持续至2028年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167333467","title":"Ocular Therapeutix宣布首例患者入组Axpaxli治疗湿性年龄相关性黄斑变性的Sol-X长期扩展试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1167333467","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167333467?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:07","pubTimestamp":1777460842,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix近日宣布，其针对湿性年龄相关性黄斑变性的创新药物Axpaxli，在Sol-X长期扩展试验中已完成首例患者入组。这一进展标志着该药物临床研究进入新阶段，为后续治疗方案的持续评估奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149954953","title":"财报前瞻｜Ocular Therapeutix本季度营收预计下滑25.15%，机构关注Axpaxli商业化路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1149954953","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149954953?lang=zh_cn&edition=full","pubTime":"2026-04-29 01:00","pubTimestamp":1777395615,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix将于2026年05月05日发布财报，市场聚焦临床管线推进与费用控制对短期财务的影响。从近期公开报道与投研评论看，市场对Ocular Therapeutix的短期基本面倾向谨慎一侧居多，核心依据集中在AXPAXLI商业化路径仍需进一步明确、以及财务端亏损与现金消耗的持续性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Ocular Therapeutix本季度营收预计下滑25.15%，机构关注Axpaxli商业化路径","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169351349","title":"Ocular Therapeutix公司Axpaxli在Sol-1试验中多个次要终点指标达到统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1169351349","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169351349?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078195,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix公司宣布，其核心产品Axpaxli在关键性的Sol-1临床试验中表现卓越，成功达到了多个预先设定的次要终点指标，且结果均显示出统计学上的显著意义。这一积极数据进一步强化了Axpaxli的疗效证据，为公司后续的监管沟通与市场拓展奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125207060","title":"Ocular Therapeutix公布Axpaxli™治疗湿性年龄相关性黄斑变性里程碑式Sol-1三期试验第52周积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1125207060","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125207060?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:02","pubTimestamp":1776078174,"startTime":"0","endTime":"0","summary":"生物技术公司Ocular Therapeutix近日公布了其核心产品Axpaxli用于治疗湿性年龄相关性黄斑变性的里程碑式Sol-1三期临床试验的最新积极结果。此次发布的数据聚焦于第52周的疗效与安全性评估，进一步验证了该疗法的持久性与可靠性。试验数据显示，在第52周的时间点，Axpaxli继续展现出显著的临床获益。安全性方面，Axpaxli在第52周的整体耐受性良好，其安全性与先前报告的数据一致，未发现新的安全性信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612200265","title":"Ocular Therapeutix, Inc.盘中异动 早盘股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612200265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612200265?lang=zh_cn&edition=full","pubTime":"2026-02-19 23:24","pubTimestamp":1771514686,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日23时24分，Ocular Therapeutix, Inc.股票出现波动，股价大幅拉升5.09%。Ocular Therapeutix, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。其相关个股中，Moolec Science Sa C/Wts 30/01/2028、Cingulate Inc C/Wts 10/12/2026 、Moolec Science Sa涨幅较大，Enveric Biosciences, Inc.、Pmgc Holdings Inc.、Theriva Biologics, Inc.较为活跃，换手率分别为1145.54%、704.50%、650.09%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Theriva Biologics, Inc.，振幅分别为247.75%、51.67%、23.44%。Ocular Therapeutix, Inc.公司简介：Oural Therapeutix Inc 是一家生物技术公司，专门从事眼部疾病和病症的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021923244697a68503&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021923244697a68503&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184607705","title":"Ocular Therapeutix：Axpaxli针对湿性年龄相关性黄斑变性的补充性Sol-R三期非劣效性试验将按计划进行，顶线数据预计于2027年第一季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1184607705","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184607705?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:05","pubTimestamp":1771329912,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix宣布，其候选药物Axpaxli用于治疗湿性年龄相关性黄斑变性的补充性Sol-R三期非劣效性试验，将依照原定方案继续推进。该试验的顶线数据结果预计将在2027年第一季度揭晓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150087091","title":"Ocular Therapeutix：第36周与52周数据显示，Axpaxli组受试者持续实现Csft控制，效果优于Aflibercept组","url":"https://stock-news.laohu8.com/highlight/detail?id=1150087091","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150087091?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:02","pubTimestamp":1771329774,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix公布的最新临床研究结果显示，在治疗周期进入第36周和52周时，接受Axpaxli治疗的受试者表现出持续的Csft（中心子视野厚度）控制效果，其疗效显著优于采用Aflibercept治疗的对照组。\n数据进一步揭示，Axpaxli治疗组在长期随访中维持了更优的解剖学结果，显示出该疗法在延缓疾病进展方面的持续潜力。这一积极成果为Ocular Therapeutix的产品线提供了重要的临床验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133060164","title":"Ocular Therapeutix 实现优效性主要终点：Axpaxli 组 74.1% 受试者在第 36 周维持视力","url":"https://stock-news.laohu8.com/highlight/detail?id=1133060164","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133060164?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:02","pubTimestamp":1771329771,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix 宣布，其试验达成优效性主要终点。数据显示，在 Axpaxli 治疗组中，高达 74.1% 的受试者在第 36 周时成功维持了视力水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146051944","title":"Ocular Therapeutix：Axpaxli在Sol-1研究中总体耐受性良好，未出现治疗相关的眼部严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1146051944","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146051944?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:02","pubTimestamp":1771329760,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix宣布，其研究性疗法Axpaxli在代号为Sol-1的临床研究中展现出良好的安全性特征。数据显示，该药物在试验过程中总体耐受性良好，且未观察到任何与治疗相关的眼部严重不良事件（SAEs）。这一积极结果为进一步评估Axpaxli的疗效和安全性提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151640631","title":"Ocular Therapeutix™将于2026年2月17日公布湿性年龄相关性黄斑变性Sol-1三期优效性试验顶线数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1151640631","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151640631?lang=zh_cn&edition=full","pubTime":"2026-02-14 06:01","pubTimestamp":1771020074,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix™宣布，计划于2026年2月17日（星期二）公布其针对湿性年龄相关性黄斑变性（Wet AMD）的Sol-1三期优效性试验的顶线数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609085309","title":"Ocular Therapeutix, Inc.盘中异动 早盘股价大涨5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609085309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609085309?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:30","pubTimestamp":1770301830,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日22时30分，Ocular Therapeutix, Inc.股票出现异动，股价快速拉升5.44%。Ocular Therapeutix, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Cytomed Therapeutics Limited涨幅较大，Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Propanc Biopharma, Inc.较为活跃，换手率分别为947.41%、827.29%、174.87%，振幅较大的相关个股有Aim Immunotech Inc.、Transcode Therapeutics, Inc.、Tuhura Biosciences, Inc.，振幅分别为13.27%、12.24%、12.03%。Ocular Therapeutix, Inc.公司简介：Oural Therapeutix Inc 是一家生物技术公司，专门从事眼部疾病和病症的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020522303097a50cea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020522303097a50cea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166740703","title":"Ocular Therapeutix 公布2025年第四季度及全年财务业绩与业务亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=1166740703","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166740703?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:08","pubTimestamp":1770293310,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix 近日披露了其2025年第四季度及全年的财务数据，并同步公布了公司在业务层面的关键进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153433346","title":"盘前｜台积电、阿斯麦、应用材料创新高，PEN涨逾13%，OCUL大涨19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153433346","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153433346?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:20","pubTimestamp":1768479651,"startTime":"0","endTime":"0","summary":"美股三大指数期货在盘前时段集体上涨。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEN","TSM","OCUL"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2518440695","title":"Ocular Therapeutix, Inc.2024财年实现净利润-1.94亿美元，同比减少140.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440695","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440695?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449669,"startTime":"0","endTime":"0","summary":"3月9日，Ocular Therapeutix, Inc.公布财报，公告显示公司2024财年净利润为-1.94亿美元，同比减少140.28%；其中营业收入为63.72百万美元，同比增加9.03%，每股基本收益为-1.22美元。从资产负债表来看，Ocular Therapeutix, Inc.总负债1.43亿美元，其中短期债务1.93百万美元，资产负债比为3.21，流动比率为0.11。机构评级：截至2025年3月9日，当前有10家机构对Ocular Therapeutix, Inc.目标价做出预测，其中目标均价为17.90美元，其中最低目标价为14.00美元，最高目标价为22.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000230abef9832&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000230abef9832&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517543948","title":"Ocular Therapeutix, Inc.盘中异动 股价大涨5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517543948","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517543948?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:43","pubTimestamp":1741185809,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时43分，Ocular Therapeutix, Inc.股票出现波动，股价大幅上涨5.23%。Ocular Therapeutix, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为447.21%、265.62%、205.52%，振幅较大的相关个股有Silexion Therapeutics Corp、Aditxt, Inc.、Radiopharm Theranostics Limited，振幅分别为25.23%、23.90%、23.49%。Ocular Therapeutix, Inc.公司简介：Oural Therapeutix Inc 是一家生物技术公司，专门从事眼部疾病和病症的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224329abe9b4a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224329abe9b4a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","OCUL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517606781","title":"Ocular Therapeutix, Inc.盘中异动 早盘快速拉升5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517606781","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517606781?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:28","pubTimestamp":1741102080,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日23时28分，Ocular Therapeutix, Inc.股票出现异动，股价急速拉升5.15%。Ocular Therapeutix, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1175.00%、1136.55%、697.38%，振幅较大的相关个股有Nkgen Biotech Inc C/Wts 31/05/2028、Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 ，振幅分别为100.00%、70.63%、66.67%。Ocular Therapeutix, Inc.公司简介：Oural Therapeutix Inc 是一家生物技术公司，专门从事眼部疾病和病症的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232800abe80038&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304232800abe80038&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OCUL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516321672","title":"Citizens Capital Markets：维持Ocular Therapeutix(OCUL.US)评级，由优于大市调整至优于大市评级, 目标价由22.00美元调整至19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516321672","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516321672?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:22","pubTimestamp":1741098129,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：维持Ocular Therapeutix(OCUL.US)评级，由优于大市调整至优于大市评级, 目标价由22.00美元调整至19.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04222248521892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["OCUL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocutx.com","stockEarnings":[{"period":"1week","weight":-0.1381},{"period":"1month","weight":-0.1389},{"period":"3month","weight":-0.1048},{"period":"6month","weight":-0.1641},{"period":"1year","weight":-0.2567},{"period":"ytd","weight":-0.2928}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0041},{"period":"3month","weight":0.055},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.1885},{"period":"ytd","weight":0.096}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ocular Therapeutix, Inc.于2006年9月12号在特拉华州成立。该公司是一家综合生物制药公司，专注于开发视网膜疾病和其他眼部疾病的治疗方法。其主要候选药物AXPAXLI（OTX-TKI）是一种用于湿性年龄相关性黄斑变性和糖尿病视网膜疾病的研究性阿昔替尼玻璃体腔内水凝胶，目前处于3期注册试验阶段。该公司还将DEXTENZA商业化，这是一种FDA批准的用于术后炎症和眼痒的皮质类固醇插入物，并基于其专有的ELUTYX生物可吸收水凝胶技术推进其他候选药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.013324},{"month":2,"riseRate":0.666667,"avgChangeRate":0.204982},{"month":3,"riseRate":0.5,"avgChangeRate":0.019654},{"month":4,"riseRate":0.583333,"avgChangeRate":-0.023422},{"month":5,"riseRate":0.5,"avgChangeRate":0.000387},{"month":6,"riseRate":0.5,"avgChangeRate":0.03349},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.032209},{"month":8,"riseRate":0.583333,"avgChangeRate":0.063842},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.090816},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.077156},{"month":11,"riseRate":0.666667,"avgChangeRate":0.140313},{"month":12,"riseRate":0.416667,"avgChangeRate":0.063013}],"exchange":"NASDAQ","name":"Ocular Therapeutix","nameEN":"Ocular Therapeutix"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ocular Therapeutix(OCUL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ocular Therapeutix(OCUL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ocular Therapeutix,OCUL,Ocular Therapeutix股票,Ocular Therapeutix股票老虎,Ocular Therapeutix股票老虎国际,Ocular Therapeutix行情,Ocular Therapeutix股票行情,Ocular Therapeutix股价,Ocular Therapeutix股市,Ocular Therapeutix股票价格,Ocular Therapeutix股票交易,Ocular Therapeutix股票购买,Ocular Therapeutix股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ocular Therapeutix(OCUL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ocular Therapeutix(OCUL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}